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cancer in Singapore for different stages of breast cancer and
hormonal therapy–related adverse effects, and 2) to determine the
association of patients’ demographic and clinical characteristics
with those preference scores. Methods: A total of 22 health states
were used to elicit preference values from 64 patients with breast
cancer. At each interview, 14 health states were randomly selected
and rated by the patient using the visual analogue scale and
standard gamble methods to derive health state preference scores,
which were recalibrated to the scale of 0 (death) and 1 (perfect
health). Results: Mean adjusted visual analogue scale scores
ranged from 0.25 (no recurrence with ischemic cerebrovascular
events) to 0.82 (no recurrence with no adverse effects). Mean adjusted
standard gamble scores ranged from 0.31 (distant recurrence with
chemotherapy-related adverse effects) to 0.80 (no recurrence with nosee front matter Copyright & 2014, International S
r Inc.
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17543.adverse effects). Adverse effects ischemic cerebrovascular events
and spine fracture resulted in the greatest decline in health state
preference scores. Age, ethnicity, education level, and prior chemo-
therapy were associated with preference scores. Having children
was not found to be associated with the preference scores. Con-
clusions: Taking into account disease progression and hormonal
therapy–related adverse effects as well as their impact on health-
related quality of life, this study quantiﬁes patients’ preference for
various breast cancer–related health states. The ﬁndings offer
valuable information for future cost-utility analysis of breast cancer
treatments.
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Breast cancer is one of the leading causes of morbidity and
mortality among women in the world. Its substantial lifetime
treatment expenditure ranges from US $20,000 to US $100,000 per
patient, with hospitalization and outpatient therapies largely
contributing to the magnitude of those expenditures [1–4]. In
Singapore, breast cancer is the most common cancer with the
highest mortality rate in the female population [5]. Moreover, it is
estimated that there are 1430 new breast cancer cases every year,
and this number increases at 3% annually [6,7]. Each woman in
Singapore has approximately a 6.1% chance of developing breast
cancer in her lifetime, and the age-adjusted incidence among
Singaporean women is one of the highest in Asia [6,7].
In addition to local treatments such as surgery and radio-
therapy, systemic treatments for breast cancer such as hormonal,
chemo-targeted, and molecular-targeted drug regimens are sig-
niﬁcant in their roles as standard treatment [8]. Over the years,
the effectiveness of hormonal therapies such as tamoxifen
and aromatase inhibitors has been well established for themanagement of estrogen-receptor–positive breast cancer [9–12].
Furthermore, adjuvant hormonal therapy has been progressively
essential in breast cancer treatment because of the increasing
incidence of early stage breast malignancy and the rising number
of breast cancer survivors. In addition to providing a signiﬁcant
reduction in disease recurrence and death, however, various
hormonal therapies are associated with adverse effects on
patients’ quality of life [13,14]. The presence of adverse effects
can lead to discontinuation of therapy and it may be more
important to patients than clinicians have yet understood [15].
Indeed, successful treatment is greatly affected by patients’
management and tolerance of adverse effects. Although the
impact of cancer therapies on survival may be indistinct, their
effect on patients’ quality of life is expected to be decidedly
negative. To understand patients’ preference for different treat-
ment outcomes, utility values can be used to quantify the impact
on patients’ health-related quality of life (HRQOL).
In previous utility assessment studies, the number of breast
cancer–related health states and treatment adverse effects evaluated
has been limited [16–19], and no study has been conducted in anociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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different stages of breast cancer and adverse effects related to
hormonal therapies in patients in Singapore, and also aimed to
identify associations of patients’ demographic and clinical char-
acteristics with those preference scores. Such preference data
will be useful for future cost-utility analyses and could improve
clinical decisions regarding breast cancer therapies.Methods
Health States
A total of 22 health states (death, perfect health, worst health,
and current health, along with 18 hypothetical health states
relating to different stages of breast cancer and adverse effects
of hormonal therapies) were developed in a previous study
through literature review and validation by an oncology expert
panel [20]. The health state descriptions illustrated common
hormonal treatment–associated adverse effects (cataract, hip
fracture, wrist fracture, spine fracture, vaginal bleeding, hot
ﬂushes, musculoskeletal disorder, pulmonary embolism, endo-
metrial cancer, deep vein thrombosis, and ischemic cardiovas-
cular events) and breast cancer–related disease stages (no
recurrence, locoregional recurrence, distant recurrence, and
new contralateral breast cancer). These health states were used
in the present study.
Preference Assessment
Study design and subjects
This cross-sectional study was approved by the National Health
Group Domain Speciﬁc Review Boards and was conducted in the
Cancer Centre of National University Cancer Institute, Singapore,
from November 2011 to January 2012.
Patients could be recruited for this study if they were female,
diagnosed with breast cancer, able to communicate in English or
Mandarin, at least 21 years old, and able to function without
apparent cognitive impairment. Patients with breast cancer were
identiﬁed by the hospital pharmacy system on the basis of
hormonal and chemotherapy agents prescribed speciﬁcally for
breast cancer treatment. Potential respondents were invited to
participate in the study during their consultation or chemo-
therapy appointments. All respondents who completed the inter-
view were reimbursed with Singapore $30 for their participation.
Study interviews
The face-to-face study interviews were conducted by two trained
interviewers in either Mandarin or English, depending on patient
preference. An interview script was preplanned and carefully
followed to reduce interviewer bias or inconsistency. The
respondents were asked to provide sociodemographic informa-
tion as well as their breast cancer treatment history, including
their experiences with symptoms or diseases after breast cancer
diagnosis. Patients also rated their current health status on a ﬁve-
point poor-to-excellent scale.
Each health state description was displayed on a laminated
card. The descriptions for different health domains of the health
states were presented in different colored text to help patients
understand and contrast the various health states. Because 22
health states were considered to be too many for accurate
evaluation as well as too much of a burden for respondents, a
core random sample approach was applied to select 14 health
states for each interviewee [21]. Each patient assessed the same
core set of 4 health states (death, perfect health, worst health,
and current health) and an additional set of 10 other health states
that were selected by a random number generator. All healthstates were presented in a random sequence to reduce potential
biases due to presentation order or respondent fatigue.
Preferences can be measured by both direct and indirect
methods. The indirect method, or the use of generic HRQOL
instruments, was not selected because Singapore-speciﬁc popu-
lation-based values for generic HRQOL instruments, such as the
EuroQol ﬁve-dimension (EQ-5D) questionnaire, are not available.
Instead, two direct valuation methods, the visual analogue scale
(VAS) and standard gamble (SG) methods, were used in this
study. For elicitation of health state preferences using VAS, a
rating scale was displayed as a line with distinct intervals from 0
to 100. Respondents were asked to read and understand all 14
cards with health state descriptions and then rank the various
health states on the scale in descending order according to their
preference. The most preferred state and the least preferred
state, which might or might not be death, were anchored at the
100 and 0 marks, respectively. Respondents were then asked to
give each of the remaining health states a value between 0 and
100, with the intervals between adjacent health states reﬂecting
the differences in preference as deemed by the patients [22–25].
In the SG assessment, a color schematic diagram illustrating a
probability wheel on a computer screen was used as a visual
support to facilitate comprehension of the process. Respondents
were offered three options: 1) to live in a particular health state
under evaluation with certainty for the rest of her life; 2) to have p
probability of living in perfect health for the rest of her life with a
(1  p) probability of immediate death; and 3) to indicate that the
previous two options were equal. The probability p was varied at
an increment of 5% until the respondent switched to a different
option or chose the third option. If any health state was rated to
be worse than death in the VAS assessment, the respondents
were also asked to choose between immediate death and a
gamble of perfect health and that particular health state [22–25].
Statistical Analysis
Preference scores obtained for each health state were presented
by means, medians, and SDs. Raw preference scores obtained
from both VAS and SG techniques were calibrated to the scale of
0 (death) and 1 (perfect health) [22]. For VAS assessment, if death
was indicated as the least preferred health state, the preference
score for the other health states would take the scale value of its
placement. In cases in which death was not indicated as the least
preferred health state, the formula (x  d)/(100  d), where d and x
denote the scale value of death and the particular health state,
respectively, was used for the calculation of the adjusted prefer-
ence score. In the SG method, if a health state was perceived to be
worse than death, the formula for calibration was as follows:
adjusted preference score ¼ p/(1  p), where p is the probability,
or raw preference score, of that particular health state. If the
health state was perceived to be more desirable than death, the
preference score for the health state was equal to the probability
p [22].
Because of the small sample size, nonparametric tests were
used in the data analysis. The Wilcoxon signed rank test was
used to examine the difference in preferences among the health
states and the difference between VAS- and SG-derived prefer-
ence scores. Spearman’s correlation coefﬁcient, the Mann-
Whitney U test, and the Kruskal-Wallis test were performed
where appropriate to determine the association between patient
characteristics (i.e., age, ethnicity, language version, education
level, having children, experience with chemotherapy, and expe-
rience with hormonal therapy) and preference scores. In addition,
the Mann-Whitney U test was used to examine the association
between experience of the common adverse effects of hormonal
therapy (i.e., hot ﬂushes and musculoskeletal disorder) and
the preference scores of the corresponding health states. All
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version 17.Results
Participant Characteristics
A total of 94 eligible patients with breast cancer were approached,
with a response rate of 68.1% (n ¼ 64). A summary of the
respondents’ characteristics is presented in Table 1. Their mean
age was 50.1  8.2 years. Most of the respondents were Chinese
(79.7%), married (76.6%), and had children (75.0%). Nearly half had
completed secondary education (48.4%) and had a gross household
monthly income between Singapore $1000 and Singapore $2999Table 1 – Characteristics of the study sample
(N ¼ 64).
Characteristics n (%)
Ethnicity
Chinese 51 (79.7)
Malay 7 (10.9)
Indian 4 (6.3)
Others 2 (3.1)
Language version
English 34 (53.1)
Chinese 29 (45.3)
Highest education level attained
Primary education and below 19 (29.7)
Secondary education 31 (48.4)
Tertiary education 14 (21.9)
Marital status
Married 49 (76.6)
Single 10 (15.6)
Divorced or widowed 5 (7.9)
Children
Yes 48 (75.0)
No 16 (25.0)
Occupation status
Employed 26 (40.6)
Unemployed 38 (59.4)
Gross household monthly income (Singapore $)
o1000 7 (10.9)
1000–2999 27 (42.2)
3000–4999 10 (15.6)
45000 18 (28.2)
Self-rated health status
Poor 7 (10.9)
Fair 29 (45.3)
Good 25 (39.1)
Very good 3 (4.7)
Breast cancer treatment history
Prior surgery 51 (79.7)
Prior chemotherapy 52 (81.3)
Prior radiotherapy 32 (50.0)
Prior hormonal therapy 27 (42.2)
Experience of adverse effects or diseases
Hot ﬂushes 16 (25.0)
Musculoskeletal disorder 7 (10.9)
Vaginal bleeding 2 (3.1)
Hip fracture 1 (1.6)
Spine fracture 1 (1.6)
Cataract 1 (1.6)
Contralateral breast cancer 1 (1.6)(42.2%). A large proportion of the respondents had undergone prior
surgery (79.7%) and chemotherapy (81.3%) for breast cancer treat-
ment. The most common adverse effects or diseases experienced
by the respondents during their breast cancer treatment were hot
ﬂushes (25.0%) and musculoskeletal disorder (10.9%). No respond-
ent had wrist fracture, deep vein thrombosis, pulmonary embo-
lism, ischemic cerebrovascular events, or endometrial cancer.
Summary of preference scores
The mean, SD, and median of the VAS- and SG-derived preference
scores for the health states assessed are presented in Table 2. After
recalibration, the mean adjusted VAS scores ranged from 0.25 (no
recurrence with ischemic cerebrovascular events) to 0.82 (no
recurrence with no adverse effects). The mean adjusted SG scores
ranged from 0.31 (distant recurrence with adverse effects from
chemotherapy) to 0.80 (no recurrence with no adverse effects).
The mean adjusted VAS and SG scores for “current health” were
0.79 and 0.76, respectively. Among all hypothetical health states
assessed, “no recurrence with any adverse effects” had the highest
mean adjusted VAS and SG scores, whereas “no recurrence with hot
ﬂushes” and “no recurrence with vaginal bleeding” had the next
highest preference scores. After excluding “worst health” and
“death,” “no recurrence with ischemic cerebrovascular events” had
the lowest mean VAS score, while “distant recurrence with
chemotherapy-related adverse effects” had the lowest SG score.
Among the adverse effects of hormonal therapy that may take place
in the “no recurrence” state, ischemic cerebrovascular events and
spine fracture resulted in the largest decline in preference scores.
Comparison among health states and between VAS- and SG-
derived preference scores
The preference scores of health states with no recurrence of
breast cancer were generally higher than those of health states
with recurrence. In addition, the preference scores of distant
recurrence health states were consistently lower than those
of locoregional recurrence health states. These trends were
observed in both VAS- and SG-derived preference scores. The
study results also showed that a few health states had preference
scores signiﬁcantly different from one another. Speciﬁcally, “no
recurrence with no adverse effects” was consistently rated higher
than all the other health states (P o 0.001) except “current
health” whereas “worst health” and “death” were rated signiﬁ-
cantly lower than all the other health states (P o 0.001). The
health states with mild adverse effects, such as hot ﬂushes and
vaginal bleeding, had higher preference scores than did recur-
rence health states (P o 0.05). The preference scores of health
states describing severe or life-threatening adverse effects such
as cataract, hip fracture, spine fracture, endometrial cancer, and
pulmonary embolism, however, were not consistently different
from those of the recurrence health states (P 4 0.05).
The mean SG scores were higher than the corresponding VAS
scores for most of the health states. The Wicoxon signed rank test
results, however, showed that the differences were not signiﬁcant
except for “no recurrence with hip fracture” (P ¼ 0.047) and
“locoregional recurrence with general adverse effects” (P ¼ 0.03).
Association between patient characteristics and preference
scores
The study results showed that age, ethnicity, language version,
and education level had a signiﬁcant association with the
preference scores of certain health states. Speciﬁcally, the
Kruskal-Wallis test and post hoc multiple comparison found that
Chinese patients had lower VAS scores for “distant recurrence
with chemotherapy adverse effects” than did Malay patients. More-
over, patients with higher education levels had higher SG scores
than did those with lower education levels for adverse effects
Table 2 – Utility valuations of breast cancer health states.
Health states N Raw VAS scores Adjusted VAS
scores
N Adjusted SG scores
Median Mean  SD Median Mean  SD Median Mean  SD
A – No reccurence with no adverse effects 35 0.90 0.83  0.14 0.85 0.82  0.14 33 0.95 0.80  0.22
B – No recurrence with hip fracture 35 0.35 0.37  0.20 0.30 0.33  0.23 34 0.45 0.43  0.36
C – No recurrence with wrist fracture 36 0.49 0.45  0.22 0.44 0.44  0.23 33 0.48 0.53  0.18
D – No recurrence with spine fracture 40 0.33 0.38  0.25 0.25 0.26  0.51 37 0.33 0.32  0.29
E – No recurrence with vaginal bleeding 35 0.68 0.60  0.22 0.69 0.58  0.23 33 0.70 0.65  0.25
F – No recurrence with deep vein
thrombosis
31 0.50 0.48  0.19 0.44 0.45  0.20 29 0.58 0.56  0.25
G – No recurrence with pulmonary
embolism
34 0.45 0.42  0.23 0.41 0.36  0.27 32 0.43 0.40  0.40
H – No recurrence with cataract 31 0.50 0.44  0.22 0.44 0.37  0.39 28 0.40 0.43  0.32
I – No recurrence with ischemic
cerebrovascular events
35 0.20 0.30  0.21 0.20 0.25  0.30 34 0.38 0.35  0.26
J – No recurrence with musculoskeletal
disorder
35 0.50 0.49  0.19 0.50 0.41  0.34 34 0.43 0.45  0.38
K – No recurrence with hot ﬂushes 36 0.63 0.62  0.20 0.61 0.60  0.19 33 0.65 0.63  0.21
L – No recurrence with endometrial cancer 33 0.40 0.43  0.21 0.40 0.40  0.22 32 0.44 0.43  0.40
M – New contralateral breast cancer 35 0.50 0.49  0.24 0.50 0.46  0.25 34 0.39 0.45  0.32
N – Locoregional recurrence with no
adverse effects
31 0.40 0.46  0.27 0.35 0.39  0.34 26 0.45 0.43  0.37
O – Locoregional recurrence with adverse
effects (general)
37 0.35 0.37  0.22 0.35 0.34  0.21 35 0.43 0.46  0.30
P – Distant recurrence with no adverse
effects
32 0.43 0.38  0.18 0.38 0.34  0.19 31 0.33 0.42  0.28
Q – Distant recurrence with adverse effects
(chemotherapy)
38 0.33 0.37  0.24 0.30 0.30  0.30 34 0.38 0.31  0.40
R – Distant recurrence with adverse effects
(hormonal therapy)
31 0.40 0.37  0.23 0.35 0.30  0.24 29 0.30 0.33  0.28
Current health 62 0.83 0.80  0.18 0.80 0.79  0.19 58 0.88 0.76  0.26
Worst health 62 0.10 0.12  0.17 0.06 0.03  0.34 56 0.05 0.28  1.76
Death 62 0.00 0.06  0.14 0.00 0.00  0.00 0
SG, standard gamble; VAS, visual analogue scale.
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Patient age was found to have a positive correlation with the VAS
scores of cataract (rs ¼ 0.36, p ¼ 0.047), deep vein thrombosis (rs ¼
0.36, p ¼ 0.04), and new contralateral breast cancer (rs ¼ 0.39, p ¼
0.02), whereas a negative association was observed between age
and the SG scores for wrist fractures (rs ¼ 0.43, p ¼ 0.01) and
ischemic cerebrovascular events (rs ¼ 0.49, p ¼ 0.003). The
respondents who chose the Chinese version of the questionnaire
had lower SG and VAS scores for “distant recurrence with
chemotherapy adverse effects” (p ¼ 0.03 and 0.01, respectively)
and lower SG scores for spine fracture (p ¼ 0.02) and endometrial
cancer (p ¼ 0.047). No signiﬁcant association was found between
having children and preference scores.
In the analysis of the association between experience and
preference scores, patients who had had chemotherapy were
found to have higher mean adjusted VAS and SG scores for
“worst health” than did those who had not. In addition, experi-
ence of hormonal therapy and its common adverse effects of hot
ﬂushes and musculoskeletal disorder were not associated with
the preference scores of the corresponding health states.Discussion
This study reports the preference scores of patients with breast
cancer in Singapore for different disease stages and adverseeffects related to hormonal therapies. Patients with breast cancer
were chosen as the study population because healthy individuals
may not have sufﬁcient knowledge speciﬁc to breast cancer
treatment to evaluate the relevant health states [26]. Never-
theless, it is notable that the patient population usually reports
higher utility values than does the general public population
[27,28]. This difference may be explained by various hypotheses
such as response shift where alterations in health status or
experience of a disease lead to a change in internal standards
for health state evaluation. In addition, patient adaptation to the
disease and public failure to predict such adaptation can be
another contributing factor for the difference [29].
As indicated by our study results, the health states with
locoregional and distant recurrence obtained lower preference
scores than did the “no recurrence” health states because the
disease progression is often accompanied with increased pain
and distress. In addition, unsurprisingly, distant recurrence
health states were given lower preference scores because
patients with distant recurrence are required to undergo harsh
cancer treatments that often lead to worse adverse effects.
Adverse effects such as ischemic cerebrovascular events and
spine fracture were found to have the lowest preference scores,
which may be explained by the life-threatening nature of ischemic
cerebrovascular events and the risk of immobility and neurological
complications related to spine fracture. These adverse effects
undoubtedly lead to a marked decline in patients’ HRQOL.
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were found to be higher than the VAS-derived scores for most
health states, which could be due to risk aversion [24,25]. In the
SG assessment, patients were required to make their decision
under uncertainty where risk-averse individuals were less likely
to take the risk of “immediate death” in the gamble option.
Therefore, the preference scores would be higher as those
patients were more inclined to choose the option of staying in
the health state with certainty and avoiding the risk of immedi-
ate death unless the gamble option offered a very favorable
probability of survival.
The preference study of oncology nurses in Singapore that
assessed the same set of health states [20] yielded results similar
to those of the present study in that both reported that ischemic
cerebrovascular events and spine fracture were the adverse
effects with the lowest preference scores among the “no recur-
rence” health states whereas vaginal bleeding and hot ﬂushes
had the least negative effects on patients’ HRQOL. Unlike the
previous study, however, the VAS-derived mean preference score
of “worst health” was positive in our study, which may reveal
that the patients were more accepting than the nurses of worst
health and perhaps more adaptable to changes in lifestyle and
mindset than outsiders may have predicted.
The association between education levels and preference
scores was observed in a few adverse effects in the present
study. Other studies with similar ﬁndings proposed that educa-
tion may act as a shield to the detrimental aspects of breast
cancer treatment by facilitating a better understanding of ways to
manage associated complications [30,31]. Our study results also
showed that chemotherapy experience led to an increase in the
preference score of worst health, which indicates that these
patients were more willing to accept that health state than were
patients without such experience. Evidence has suggested that
medical knowledge or experience with a disease or condition
may affect subjects’ valuation of health states [32]. The favorable
experience with the chemotherapy outcomes and cognitive
adaptation may explain the effect of chemotherapy experience
on preference scores.
Our study used VAS and SG for preference measurement.
These two methods have been shown to be practical, reliable, and
valid for use in numerous populations, including those in
Singapore settings [33,34]. Preference studies using these meth-
ods have reported high completion rates, and VAS has the
additional beneﬁt of a lower cost [33]. These descriptions accord
with our study’s high completion rate, indicating that respond-
ents in general did not encounter problems during preference
assessment. Moreover, the framing effect was minimized with
the use of perfect health and immediate death health states as
the two anchor points in our study. As such, the health state
descriptions and assessment procedures herein may be applied
to future preference studies in the general public or other patient
populations to generate preference scores for comparison. In
addition, the preference data reported in this study can be useful
for cost-utility analyses of breast cancer treatments, particularly
hormonal therapies. With the consistent entry of new and costly
options for breast cancer treatment, such economic evaluations
will be essential in the allocation of limited health care resources
and the improvement of clinical decision making for optimal
cancer care.
One of the limitations of our study is the small sample size.
Moreover, to reduce respondent burden, patients were asked to
assess only 14 of the 22 health states under evaluation. Although
there is no minimum sample size requirement for preference
assessment, a larger sample would have been more desirable for
the investigation of the associations between patient character-
istics and preference scores. Furthermore, the inclusion of only
outpatients may have led to a selection bias toward those withbetter health and mobility, as no patients with breast cancer from
inpatient settings or terminal care facilities were recruited. These
patients were excluded because they were likely to have difﬁculty
understanding and completing the interview. To reduce the time
and cognitive burden of the respondents, the ping-pong approach
was not used in the SG assessment. It is acknowledged that using
the 50% perfect health as the starting point may have resulted in
narrower ranges of preference scores and that using the ping-
pong approach could have minimized the starting point bias.Conclusions
Taking into account disease progression and hormonal therapy–
related adverse effects as well as their impact on HRQOL, this
study quantiﬁes patients’ preference for various breast cancer–
related health states. The ﬁndings offer valuable information for
future cost-utility analysis of breast cancer treatments, which
can aid clinical decision making regarding cancer therapies. In
addition, this study may be used as a basis for future research to
obtain utility data from other Asian populations.Acknowledgments
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